A first-in-kind MAPK13 inhibitor that can correct stem cell reprogramming and post-injury disease.
Zhang Y, Wu K, Mao D, Iberg CA, Yin-Declue H, Sun K, Wikfors HA, Keeler SP, Li M, Young D, Yantis J, Crouch EC, Chartock JR, Han Z, Byers DE, Brody SL, Romero AG, Holtzman MJ.
Zhang Y, et al. Among authors: brody sl.
bioRxiv [Preprint]. 2024 Aug 22:2024.08.21.608990. doi: 10.1101/2024.08.21.608990.
bioRxiv. 2024.
PMID: 39229202
Free PMC article.
Preprint.